Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.


Treatment of Decompensated Heart Failure

Echocardiography in the Detection and Monitoring of Heart Failure


European Cardiovascular Disease 2006;2(1):1–6

Emerging Cardiac Resynchronisation Therapy Indications


Eurpoean Cardiology 2011;7(1):29–33

Dynamic Bi-level Positive Airway Pressure Ventilation for the Treatment of Central Sleep Apnoea in Patients with Chronic Heart Failure


European Cardiovascular Disease 2006;2(1):106